2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d] pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 14, 2011, Pages 4355-4365

  Gangjee, Aleem ^a   Namjoshi, Ojas A ^a   Keller, Staci N ^b   Smith, Charles D ^b  

^a DUQUESNE UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antimitotic; Cytotoxic; Sonogashira coupling; Tumor resistance reversal

Indexed keywords

2 AMINO 4 METHYL 5 PHENYLETHYL 7 N BENZYL PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; 7 BENZYL 4 METHYL 5 [2 (2 CHLOROPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 AMINE; 7 BENZYL 4 METHYL 5 [2 (2,3,4 TRIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 AMINE; 7 BENZYL 4 METHYL 5 [2 (2,3,4,5 TETRAMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 AMINE; 7 BENZYL 4 METHYL 5 [2 (2,3,5 TRIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 AMINE; 7 BENZYL 4 METHYL 5 [2 (2,4 DIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 AMINE; 7 BENZYL 4 METHYL 5 [2 (2,4,5 TRIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 AMINE; 7 BENZYL 4 METHYL 5 [2 (2,6 DIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 AMINE; 7 BENZYL 4 METHYL 5 [2 (3,4 DIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 AMINE; 7 BENZYL 4 METHYL 5 [2 (3,5 DIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 AMINE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; N [7 BENZYL 4 METHYL 5 [(2 CHLOROPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N 2,2 DIMETHYPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2 CHLOROPHENYL)ETHYNYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,3,4 TRIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N 2,2 DIMETHYPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,3,4 TRIMETHOXYPHENYL)ETHYNYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,3,4,5 TETRAMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,3,4,5 TETRAMETHOXYPHENYL)ETHYNYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,3,5 TRIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,4 DIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,4 DIMETHOXYPHENYL)ETHYNYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,4,5 TRIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,4,5 TRIMETHOXYPHENYL)ETHYNYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,6 DIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(2,6 DIMETHOXYPHENYL)ETHYNYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(3,4 DIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N 2,2 DIMETHYPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(3,4 DIMETHOXYPHENYL)ETHYNYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(3,5 DIMETHOXYPHENYL)ETHYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; N [7 BENZYL 4 METHYL 5 [(3,5 DIMETHOXYPHENYL)ETHYNYL] 7H PYRROLO[2,3 D]PYRIMIDIN 2 YL] N (2,2 DIMETHYLPROPANOYL) 2,2 DIMETHYLPROPANAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; REVERSAL REACTION; SONOGASHIRA REACTION; TUMOR RESISTANCE; TUMOR RESISTANCE REVERSAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MITOSIS; MOLECULAR STRUCTURE; PYRIMIDINES; PYRROLES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

VINCA;

EID: 79959945184     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.05.030     Document Type: Article

References (46)

1. Gangjee, A.; Namjoshi, O. A.; Keller, S. N.; Smith, C. D. Abstract of Papers, 233rd National Meeting of the American Chemical Society, Chicago, IL; American Chemical Society: Washington, DC, 2007; MEDI 169.
2. M.A. Jordan, and L. Wilson Nat. Rev. Cancer 4 2004 253
3. J. Cortes, and J. Baselga Oncologist 12 2007 271
4. R. Heald, and E. Nogales J. Cell Sci. 115 2002 3
5. E. Rowinsky, and R.C. Donehower Antimicrotubule Agents V.T. DeVita, S. Hellman, S.A. Rosenburg, Cancer, Principles and Practice of Oncology, 6th ed 2001 Lippincott-Raven Philadelphia, PA 431 452
6. C. Kanthou, and M.T. Tozer Int. J. Exp. Pathol. 90 2009 284
7. R.O. Carlson Expert Opin. Invest. Drugs 17 2008 707
8. http://www.cancer.gov/cancertopics/druginfo/fda-ixabepilone.
9. A. Conlin, M. Fornier, C. Hudis, S. Kar, and P. Kirkpatrick Nat. Rev. Drug Disc. 6 2007 953
10. A.T. Fojo, and M. Menefee Semin. Oncol. 32 2005 S3
11. B.I. Sikic, G.A. Fisher, B.L. Lum, J. Halsey, L. Beketic-Oreskovic, and G. Chen Cancer Chemother. Pharmacol. 40 1997 S13
12. V. Ling Cancer Chemother. Pharmacol. 40 1997 S3
13. B. Tan, D. Piwnica-Worms, and L. Ratner Curr. Opin. Oncol. 12 2000 450
14. C.E. Grant, G. Valdimarsson, D.R. Hipfner, K.C. Almquist, S.P. Cole, and R.G. Deeley Cancer Res. 54 1994 357
15. G.D. Kruh, A. Chan, K. Myers, K. Gaughan, T. Miki, and S.A. Aaronson Cancer Res. 54 1994 1649
16. S.P. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M. Duncan, and R.G. Deeley Science 258 1992 1650
17. S. Nobili, I. Landini, B. Giglioni, and E. Mini Curr. Drug Targets 7 2006 861
18. D.D. Ross Best Pract. Res. Clin. Haematol. 17 2004 641
19. R. Rosell, G. Scagliotti, K.D. Danenberg, R.V.N. Lord, G. Bepler, S. Novello, J. Cooc, L. Crino, J.J. Sanchez, M. Taron, C. Boni, F. De Marinis, M. Tonato, M. Marangolo, F. Gozzelino, F. Di Costanzo, M. Rinaldi, D. Salonga, and C. Stephens Oncogene 22 2003 3548
20. C. Dumontet, S. Isaac, P.-J. Souquet, F. Bejui-Thivolet, Y. Pacheco, N. Peloux, A. Frankfurter, R. Luduena, and M. Perol Bull. Cancer 92 2005 E25
21. P. Seve, S. Isaac, O. Tredan, P.-J. Souquet, Y. Pacheco, M. Perol, L. Lafanechere, A. Penet, E.-L. Peiller, and C. Dumontet Clin. Cancer Res. 11 2005 5481
22. S. Tommasi, A. Mangia, R. Lacalamita, A. Bellizzi, V. Fedele, A. Chiriatti, C. Thomssen, N. Kendzierski, A. Latorre, V. Lorusso, F. Schittulli, F. Zito, M. Kavallaris, and A. Paradiso Int. J. Cancer 120 2007 2078
23. S. Mozzetti, C. Ferlini, P. Concolino, F. Filippetti, G. Raspaglio, S. Prislei, D. Gallo, E. Martinelli, F.O. Ranelletti, G. Ferrandina, and G. Scambia Clin. Cancer Res. 11 2005 298
24. G. Ferrandina, G.F. Zannoni, E. Martinelli, A. Paglia, V. Gallotta, S. Mozzetti, G. Scambia, and C. Ferlini Clin. Cancer Res. 12 2006 2774
25. A. Gangjee, J. Yu, J.E. Copper, and C.D. Smith J. Med. Chem. 50 2007 3290
26. Moore, M. D.; Namjoshi, O. A.; Gangjee, A.; Wildfong, P. L. D., unpublished results.
27. Namjoshi, O. A. Ph.D. Thesis, Duquesne University, Pittsburgh, PA, May 2009.
28. T. Hundertmark, A.F. Littke, S.L. Buchwald, and G.C. Fu Org. Lett. 2 2000 1729
29. L.K. Syper, K. Kloc, and J. Mlochowski Tetrahedron 36 1980 123
30. J.M. Blatchly, J.F.W. McOmie, and J.B. Searle J. Chem. Soc. C 10 1969 1050
31. H.W. Dorn, W.H. Warren, and J.L. Bullock J. Am. Chem. Soc. 61 1939 144
32. We thank the National Cancer Institute for performing the in vitro antitumor evaluation in their 60 tumor preclinical screening program.
33. E. Schneider, J.K. Horton, C.H. Yang, M. Nakagawa, and K.H. Cowan Cancer Res. 54 1994 152
34. C.D. Smith, J.T. Zilfou, K. Stratmann, G.M.L. Patterson, and R.E. Moore Mol. Pharm. 47 1995 241
35. C.D. Smith, and J.T. Zilfou J. Biol. Chem. 270 1995 28145
36. J.T. Zilfou, and C.D. Smith Oncol. Res. 7 1995 435
37. X. Zhang, and C.D. Smith Mol. Pharm. 49 1996 288
38. D.L. Lawrence, J.E. Copper, and C.D. Smith J. Med. Chem. 44 2001 594
39. C.D. Smith, C.B. Myers, J.T. Zilfou, S.N. Smith, and D.S. Lawrence Oncol. Res. 12 2000 219
40. B.D. Lee, Z.-J. Li, D.J. French, Y. Zhuang, Z. Xia, and C.D. Smith J. Med. Chem. 47 2004 1413
41. P. Skehan, R. Stoneng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd J. Natl. Cancer Inst. 82 1990 1107
42. R.B. Vallee Methods Enzymol. 134 1986 89
43. R. Bai, G.R. Pettit, and E. Hamel Biochem. Pharmacol. 39 1990 1941
44. http://dtp.nci.nih.gov/branches/btb/ivclsp.html.
45. S. Mehta, and R. Larock J. Org. Chem. 75 2010 1652
46. S. Doherty, J.G. Knight, J.P. McGrady, A.M. Ferguson, N.A.B. Ward, R.W. Harrington, and W. Clegg Adv. Synth. Catal. 352 2010 201